Search Results
Abstracts
Baseline gut-associated microbial signatures may help predict HIV-1 viral control after treatment interruption
A. Borgognone
Presented at:
International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment 2020
Slidesets
Is TDM Still Needed / Useful ? | Nancy Sheehan
Presented at:
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023
Slidesets
The Prevention Pipeline and Clinical Trial Design for PrEP - Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Presented at:
HIV Prevention Summit 2021
Slidesets
R&D Pipeline & Clinical Trial Design -Linda-Gail Bekker, DCH, FCP(SA), PhD
Presented at:
HIV Prevention Summit 2021
Slidesets
State of the Art Lecture: Rational design of doravirine (DOR): From bench to patients | Daria Hazuda, PhD
Presented at:
HIV DART and Emerging Viruses 2018
Abstracts
The Covid-19 pandemic and its effect on the sex market in Mexico City
C. Chivardi
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021
Slidesets
Practical guidance on pediatrics NAFLD (incl. clinical cases) -- Alastair Baker, MB, ChB, FRCP, FRCPCH, MBA
Presented at:
European Workshop on NASH in Clinical Practice 2019